WebMay 23, 2024 · Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903 Linda Mileshkin a, ⁎ ,1 , Richard Edmondson b,c,1 ,RachelL.O'Connell d , Katrin M. Sjoquist d ,JohnAndrews d , WebPARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 ... PARAGON is an investigator-initiated single arm open-label multicentre phase 2 trial, designed to evaluate the activity of anastrozole in postmenopausal patients with a wide …
Phase 2 study of anastrozole in patients with estrogen receptor ...
Web2. Materials and methods PARAGON is a Gynecologic Cancer InterGroup trial led by the Australian New Zealand Gynecological Oncology Group (ANZGOG) and coordinated by the National Health and Medical Research Council (NHMRC)Clinical Trials Centre, University of Sydney. Thecollaborating groups are the UK National Cancer Research Institute (NCRI) via WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive recurrent gynecological cancers. ... Median progression-free survival was 2.7 months (95% CI, 2.0–2.8 months). The median duration of clinical benefit was 2.8 ... coachmen beyond 22c li3
A phase 2 study of anastrozole in patients with oestrogen …
WebJan 18, 2024 · A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Publication Type: Journal Article: Year of Publication: 2024: Authors WebApr 1, 2024 · 2. Materials and methods PARAGON is a Gynecologic Cancer InterGroup trial led by the Australian New Zealand Gynecological Oncology Group (ANZGOG) and coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney. WebMay 20, 2024 · The phase 2 PARAGON trial, which investigated anastrozole in a variety of gynecologic cancers, included a cohort of 41 postmenopausal recurrent granulosa cell tumor patients with estrogen... coachmen beyond 22c li3 for sale